- Published on
One Type of Diabetes Responds Better to a Weekly GLP-1 Drug Than to Insulin
- Authors
- Name
- DeepHorus
A new study has found that a weekly injection of the GLP-1 drug dulaglutide is significantly more effective than daily insulin shots for treating a rare form of diabetes linked to the blood disorder transfusion-dependent beta-thalassaemia (TDT). This development could simplify treatment for affected patients and offers better blood sugar control with fewer side effects. The research, published in the journal Diabetologia, was led by a team from Ain Shams University in Egypt.
TDT is a genetic condition requiring regular blood transfusions, which can cause iron overload that damages the pancreas. This damage prevents normal insulin production, leading to a unique form of diabetes that shares features of both type 1 and type 2 diabetes. Previous standard treatments often involved metformin, followed by insulin injections for those who did not respond.
The clinical trial enrolled 80 adolescents aged 10 to 18 with TDT-induced diabetes who were unresponsive to metformin. Half the group received weekly dulaglutide injections, while the other half received daily insulin injections. Their health metrics were tracked for 24 weeks, with participants asked to maintain their usual lifestyle habits throughout the study.
The results showed clear advantages for dulaglutide. Participants on the GLP-1 drug experienced greater reductions in average blood sugar levels and fewer dangerous swings in blood glucose. They also spent more time in healthy glucose ranges and did not experience the significant weight gain observed in the insulin group.
An intriguing secondary finding was that dulaglutide appeared to help reduce iron overload, a key underlying problem in TDT. Researchers noted the therapy improved glycaemic control and variability without increasing the risk of hypoglycemia. The study is the first to assess dulaglutide's efficacy in this specific patient population.
The mechanism involves dulaglutide mimicking the natural GLP-1 hormone, which prompts the pancreas to produce more insulin and slows digestion. This approach seems to support remaining pancreatic function rather than just supplementing with external insulin, which is crucial for a condition where the pancreas is already damaged. The findings suggest a promising new therapeutic modality.
While the results are promising, the researchers emphasize that larger studies are needed to confirm these benefits and fully understand how GLP-1 agonists regulate blood sugar and iron levels in TDT diabetes. Future research will aim to involve more participants and explore the long-term effects of this treatment strategy for vulnerable young patients.
